Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine.
EHV-1
Inactivated vaccine
Live vaccine
Vaccination coverage
Virus-neutralizing antibody
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
06 Aug 2019
06 Aug 2019
Historique:
received:
25
04
2019
accepted:
31
07
2019
entrez:
8
8
2019
pubmed:
8
8
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Equine herpesvirus type 1 (EHV-1) infection is a major cause of pyrexias in winter among Japanese racehorses. In 2014-2015, the Japan Racing Association (JRA) changed the EHV-1 vaccine from an inactivated vaccine to a live vaccine (both produced by Nisseiken). To evaluate the effect of changing the vaccines, the capacities of these vaccines to induce virus-neutralizing (VN) antibodies were compared, and an epizootiological investigation of EHV-1 was performed at the JRA Ritto Training Center during epizootic periods from 2010-2011 to 2016-2017. Three-year-old horses that received the first dose of live vaccine showed higher geometric mean (GM) VN titers (205 and 220) than those that received inactivated vaccine (83, P < 0.05). The response rates after vaccination with the live vaccine (76 and 90%) were higher than that after vaccination with inactivated vaccine (42%, P < 0.05). Four-year-old horses from 2015 to 2017 that had received the live vaccine in the previous epizootic periods had higher GM titers (205 to 246) than those from 2011 to 2014, which had received the inactivated vaccine (139 to 164, P < 0.05). The estimated numbers of horses infected with EHV-1 or EHV-4, or both, in 2011-2012 (29 [95%CI: 21-37]) and 2013-2014 (37 [95%CI: 27-47]) were higher than those in the other periods (7 [95%CI: 2-12] to 16 [95%CI: 9-23]). Likewise, the seroconversion rates to EHV-1 in horses that stayed at the training center in 2011-2012 (66.0%) and 2013-2014 (52.0%) were higher than those in the other periods (12.0 to 28.6%). The live EHV-1 vaccine is highly immunogenic and provides greater VN antibody responses than the inactivated vaccine. Unlike the period when the policy was to use inactivated vaccine, there was no detectable epizootic EHV-1 infection at the training center during three consecutive periods after the introduction of the live vaccine. These results suggest that the replacement of inactivated vaccine with live vaccine, together with the achievement of high vaccination coverage, reinforced the herd effect, and contributed to better control of EHV-1 epizootics in the training center.
Sections du résumé
BACKGROUND
BACKGROUND
Equine herpesvirus type 1 (EHV-1) infection is a major cause of pyrexias in winter among Japanese racehorses. In 2014-2015, the Japan Racing Association (JRA) changed the EHV-1 vaccine from an inactivated vaccine to a live vaccine (both produced by Nisseiken). To evaluate the effect of changing the vaccines, the capacities of these vaccines to induce virus-neutralizing (VN) antibodies were compared, and an epizootiological investigation of EHV-1 was performed at the JRA Ritto Training Center during epizootic periods from 2010-2011 to 2016-2017.
RESULTS
RESULTS
Three-year-old horses that received the first dose of live vaccine showed higher geometric mean (GM) VN titers (205 and 220) than those that received inactivated vaccine (83, P < 0.05). The response rates after vaccination with the live vaccine (76 and 90%) were higher than that after vaccination with inactivated vaccine (42%, P < 0.05). Four-year-old horses from 2015 to 2017 that had received the live vaccine in the previous epizootic periods had higher GM titers (205 to 246) than those from 2011 to 2014, which had received the inactivated vaccine (139 to 164, P < 0.05). The estimated numbers of horses infected with EHV-1 or EHV-4, or both, in 2011-2012 (29 [95%CI: 21-37]) and 2013-2014 (37 [95%CI: 27-47]) were higher than those in the other periods (7 [95%CI: 2-12] to 16 [95%CI: 9-23]). Likewise, the seroconversion rates to EHV-1 in horses that stayed at the training center in 2011-2012 (66.0%) and 2013-2014 (52.0%) were higher than those in the other periods (12.0 to 28.6%).
CONCLUSIONS
CONCLUSIONS
The live EHV-1 vaccine is highly immunogenic and provides greater VN antibody responses than the inactivated vaccine. Unlike the period when the policy was to use inactivated vaccine, there was no detectable epizootic EHV-1 infection at the training center during three consecutive periods after the introduction of the live vaccine. These results suggest that the replacement of inactivated vaccine with live vaccine, together with the achievement of high vaccination coverage, reinforced the herd effect, and contributed to better control of EHV-1 epizootics in the training center.
Identifiants
pubmed: 31387602
doi: 10.1186/s12917-019-2036-0
pii: 10.1186/s12917-019-2036-0
pmc: PMC6683523
doi:
Substances chimiques
Antibodies, Viral
0
Vaccines, Inactivated
0
Viral Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280Références
J Vet Med Sci. 1992 Apr;54(2):207-11
pubmed: 1318750
Vaccine. 2006 Apr 24;24(17):3636-45
pubmed: 16513225
J Vet Med Sci. 2009 Nov;71(11):1439-48
pubmed: 19959893
Vaccine. 2010 Jul 19;28(32):5203-11
pubmed: 20538091
Vet Microbiol. 2013 May 31;164(1-2):18-26
pubmed: 23434015
J Vet Med Sci. 2013;75(9):1209-12
pubmed: 23595119
J Equine Sci. 2013;24(4):71-4
pubmed: 24834005
Clin Vaccine Immunol. 2014 Aug;21(8):1070-6
pubmed: 24872513
J Vet Med Sci. 2016 Feb;78(2):309-11
pubmed: 26424485
Vet Microbiol. 2018 Aug;222:18-24
pubmed: 30080668
Nihon Juigaku Zasshi. 1987 Dec;49(6):1087-96
pubmed: 3430919
Adv Virus Res. 1995;45:153-90
pubmed: 7793324
J Vet Med Sci. 1998 Oct;60(10):1133-7
pubmed: 9819768